

Persistence and Adherence With Topical Glaucoma The

American Journal of Ophthalmology

140, 598.e1-598.e11

DOI: [10.1016/j.ajo.2005.04.051](https://doi.org/10.1016/j.ajo.2005.04.051)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Topical Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution. <i>Drugs and Aging</i> , 2006, 23, 977-995.	2.7	21
2	Health Literacy and Adherence to Glaucoma Therapy. <i>American Journal of Ophthalmology</i> , 2006, 142, 223-226.e2.	3.3	142
3	Persistence and Adherence With Topical Glaucoma Therapy. <i>Yearbook of Ophthalmology</i> , 2006, 2006, 70-72.	0.0	0
4	Dirty little secrets. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 195-196.	2.6	9
5	Microprocessor controlled compliance monitor for eye drop medication. <i>British Journal of Ophthalmology</i> , 2006, 90, 830-832.	3.9	18
6	Ocular Comfort of Combination Glaucoma Therapies: Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide 2%/Timolol 0.5%. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2007, 23, 372-376.	1.4	18
7	What's in a name? Medication terms: what they mean and when to use them. <i>British Journal of Ophthalmology</i> , 2007, 91, 1422-1424.	3.9	2
8	Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. <i>British Journal of Ophthalmology</i> , 2007, 91, 62-68.	3.9	32
9	Risk Factors and Open-angle Glaucoma: Classification and Application. <i>Journal of Glaucoma</i> , 2007, 16, 406-418.	1.6	193
10	Depressive Symptomatology, Medication Persistence, and Associated Healthcare Costs in Older Adults With Glaucoma. <i>Journal of Glaucoma</i> , 2007, 16, 513-520.	1.6	48
11	Selective Laser Trabeculoplasty. <i>Survey of Ophthalmology</i> , 2007, 52, 634-654.	4.0	74
12	Accounting for Restart Rates in Evaluating Persistence with Ocular Hypotensives. <i>Ophthalmology</i> , 2007, 114, 648-652.	5.2	41
13	Evaluation of Practice Patterns for the Care of Open-angle Glaucoma Compared with Claims Data. <i>Ophthalmology</i> , 2007, 114, 1599-1606.	5.2	137
14	The TRAVATAN Dosing Aid Accurately Records When Drops Are Taken. <i>American Journal of Ophthalmology</i> , 2007, 143, 699-701.	3.3	46
15	A Gap Analysis Approach to Assess Patient Persistence with Glaucoma Medication. <i>American Journal of Ophthalmology</i> , 2007, 144, 520-524.	3.3	25
16	Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 100-111.	3.0	18
17	A Composite Screening Tool for Medication Reviews of Outpatients. <i>Drugs and Aging</i> , 2007, 24, 733-760.	2.7	39
18	Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database. <i>Current Medical Research and Opinion</i> , 2007, 23, 3009-3016.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS). , 2007, 48, 5052.		238
20	Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 602-611.	2.6	21
22	Doctorâ€™Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. <i>Ophthalmology</i> , 2008, 115, 1320-1327.e3.	5.2	251
23	Adherence and Persistence with Glaucoma Therapy. <i>Survey of Ophthalmology</i> , 2008, 53, S57-S68.	4.0	246
24	Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. <i>British Journal of Ophthalmology</i> , 2008, 92, 729-734.	3.9	29
25	Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. <i>Canadian Journal of Ophthalmology</i> , 2008, 43, 33-41.	0.7	15
26	Ocular Health in Sleep Apnea: A Comprehensive Overview. <i>Neuro-Ophthalmology</i> , 2008, 32, 127-136.	1.0	2
27	Costs and persistence of carbonic anhydrase inhibitor versus alphaâ€™2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UKâ€™GPRD database. <i>Current Medical Research and Opinion</i> , 2008, 24, 1519-1527.	1.9	9
28	Improving Eye Drop Treatment for Glaucoma through Better Adherence. <i>Optometry and Vision Science</i> , 2008, 85, 374-375.	1.2	14
29	The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. <i>British Journal of Ophthalmology</i> , 2008, 92, 7-12.	3.9	46
30	Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database. <i>Journal of Medical Economics</i> , 2008, 11, 485-497.	2.1	7
31	Predictors of and Barriers Associated With Poor Follow-up in Patients With Glaucoma in South India. <i>JAMA Ophthalmology</i> , 2008, 126, 1448.	2.4	58
32	Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension. <i>Cardiology in Review</i> , 2008, 16, 95-108.	1.4	21
33	Barriers to Glaucoma Drug Delivery. <i>Journal of Glaucoma</i> , 2008, 17, 147-156.	1.6	130
34	Physician Beliefs and Behaviors Related to Glaucoma Treatment Adherence. <i>Journal of Glaucoma</i> , 2008, 17, 690-698.	1.6	21
35	Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model. <i>European Journal of Ophthalmology</i> , 2008, 18, 44-51.	1.3	7
36	Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid. <i>Clinical Ophthalmology</i> , 2008, 2, 769.	1.8	22
37	Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. <i>Patient Preference and Adherence</i> , 2008, 2, 303.	1.8	32

#	ARTICLE	IF	CITATIONS
38	Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database. <i>Clinical Ophthalmology</i> , 2008, 2, 321.	1.8	7
39	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. <i>Clinical Ophthalmology</i> , 2008, , 117.	1.8	13
40	Glaucoma Patients' Trust in the Physician. <i>Journal of Ophthalmology</i> , 2009, 2009, 1-5.	1.3	9
41	First-year treatment costs among new initiators of topical prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2009, 3, 637.	1.8	10
42	Characteristics of respondents with glaucoma and dry eye in a national panel survey. <i>Clinical Ophthalmology</i> , 2009, 3, 645.	1.8	12
43	Carbonic anhydrase inhibitors. , 2009, , 407-419.		4
44	Primary open angle glaucoma. , 2009, , 239-265.		6
45	Medical treatment of glaucoma: general principles. , 2009, , 345-358.		2
47	Noncompliance with drug therapy of glaucoma: a review about intervening factors. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2009, 45, 453-459.	1.2	9
48	Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 555-562.	1.4	17
49	The Impact of Ocular Adverse Effects in Patients Treated With Topical Prostaglandin Analogs: Changes in Prescription Patterns and Patient Persistence. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 145-152.	1.4	77
50	Unpredictability of glaucoma progression. <i>Current Medical Research and Opinion</i> , 2009, 25, 2167-2177.	1.9	6
51	The Safety and Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%/Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension. <i>Journal of Glaucoma</i> , 2009, 18, 293-300.	1.6	67
52	First-year treatment patterns among new initiators of topical prostaglandin analogs. <i>Current Medical Research and Opinion</i> , 2009, 25, 851-858.	1.9	21
53	Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. <i>British Journal of Ophthalmology</i> , 2009, 93, 316-321.	3.9	96
54	Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994â€“2005. <i>Eye</i> , 2009, 23, 1098-1110.	2.1	16
55	An assessment of readiness for behaviour change in patients prescribed ocular hypotensive therapy. <i>Eye</i> , 2009, 23, 1668-1674.	2.1	8
56	Adherence with Topical Glaucoma Medication Monitored Electronically. <i>Ophthalmology</i> , 2009, 116, 191-199.	5.2	262

#	ARTICLE	IF	CITATIONS
57	The Cost-effectiveness of Routine Office-based Identification and Subsequent Medical Treatment of Primary Open-Angle Glaucoma in the United States. <i>Ophthalmology</i> , 2009, 116, 823-832.	5.2	72
58	Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma. <i>Ophthalmology</i> , 2009, 116, 1097-1105.	5.2	163
59	Doctor-Patient Communication in Glaucoma Care. <i>Ophthalmology</i> , 2009, 116, 2277-2285.e3.	5.2	46
60	A Comprehensive Perspective on Patient Adherence to Topical Glaucoma Therapy. <i>Ophthalmology</i> , 2009, 116, S30-S36.	5.2	205
61	Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma. <i>Clinical Drug Investigation</i> , 2009, 29, 111-120.	2.2	13
62	Cost of Illness of Glaucoma. <i>Pharmacoeconomics</i> , 2009, 27, 189-198.	3.3	30
63	Glaucoma medication persistence with a fixed combination versus multiple bottles. <i>Current Medical Research and Opinion</i> , 2009, 25, 2543-2547.	1.9	39
64	Determinants of Adherence to Glaucoma Medical Therapy in a Long-term Patient Population. <i>Journal of Glaucoma</i> , 2009, 18, 238-243.	1.6	113
65	Selective Laser Trabeculoplasty for Primary Angle Closure With Persistently Elevated Intraocular Pressure After Iridotomy. <i>Journal of Glaucoma</i> , 2009, 18, 563-566.	1.6	37
66	An Exploratory Study of Factors Influencing Glaucoma Treatment Adherence. <i>Journal of Glaucoma</i> , 2010, 19, 66-72.	1.6	112
67	iStent [®] : trabecular micro-bypass stent for open-angle glaucoma. <i>Expert Review of Ophthalmology</i> , 2010, 5, 443-450.	0.6	1
68	Electronic compliance monitoring of topical treatment after ophthalmic surgery. <i>International Ophthalmology</i> , 2010, 30, 385-390.	1.4	53
69	First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. <i>BMC Ophthalmology</i> , 2010, 10, 4.	1.4	16
70	Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. <i>BMC Ophthalmology</i> , 2010, 10, 5.	1.4	18
71	Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. <i>Eye</i> , 2010, 24, 624-631.	2.1	41
72	Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey. <i>Clinical Ophthalmology</i> , 2010, 4, 731.	1.8	19
73	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. <i>Clinical Ophthalmology</i> , 2010, 4, 437.	1.8	3
74	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. <i>Current Medical Research and Opinion</i> , 2010, 26, 2769-2777.	1.9	6

#	ARTICLE	IF	CITATIONS
75	Primary Open Angle Glaucoma. , 2010, , 399-419.		0
76	Physiciansâ€™ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma. <i>Current Medical Research and Opinion</i> , 2010, 26, 957-963.	1.9	12
78	Programs to optimize adherence in glaucoma. <i>Optometry - Journal of the American Optometric Association</i> , 2010, 81, 339-350.	0.6	21
79	Glaucoma among patients enrolled in a national vision care plan. <i>Optometry - Journal of the American Optometric Association</i> , 2010, 81, 663-670.	0.6	2
80	Videotaped Evaluation of Eyedrop Instillation in Glaucoma Patients with Visual Impairment or Moderate to Severe Visual Field Loss. <i>Ophthalmology</i> , 2010, 117, 2345-2352.	5.2	87
81	Are You Compliant With Addressing Glaucoma Adherence?. <i>American Journal of Ophthalmology</i> , 2010, 149, 1-3.	3.3	32
82	Use of Glaucoma Medications: State of the Science and Directions for Observational Research. <i>American Journal of Ophthalmology</i> , 2010, 150, 569-574.e9.	3.3	23
83	Fixed Combination of Latanoprost and Timolol vs Individual Components for Primary Open-Angle Glaucoma or Ocular Hypertension. <i>JAMA Ophthalmology</i> , 2010, 128, 165.	2.4	42
84	Persistence with Prostaglandin Agonist Use with and without Adjunctive Therapy for Glaucoma Patients. <i>Patient</i> , 2011, 4, 133-141.	2.7	4
85	Recent Advances in Ocular Drug Delivery Systems. <i>Polymers</i> , 2011, 3, 193-221.	4.5	161
87	Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. <i>Acta Ophthalmologica</i> , 2011, 89, e300-5.	1.1	28
88	Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database. <i>Clinical Ophthalmology</i> , 2011, 5, 361.	1.8	5
89	Measurement of Adherence to Brimonidine Therapy for Glaucoma Using Electronic Monitoring. <i>Journal of Glaucoma</i> , 2011, 20, 502-508.	1.6	40
90	Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma. <i>Clinical Ophthalmology</i> , 2011, 5, 1515.	1.8	7
91	Adherence: compliance, persistence and concordance in the management of glaucoma. Part 1. <i>International Journal of Ophthalmic Practice</i> , 2011, 2, 260-264.	0.0	1
92	Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. <i>Clinical Ophthalmology</i> , 2011, 5, 751.	1.8	25
93	Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population. <i>JAMA Ophthalmology</i> , 2011, 129, 643.	2.4	34
94	A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. <i>BMC Ophthalmology</i> , 2011, 11, 13.	1.4	2

#	ARTICLE	IF	CITATIONS
95	Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. <i>Patient Preference and Adherence</i> , 2011, 5, 441.	1.8	127
96	Glaucoma Medication Adherence. <i>JAMA Ophthalmology</i> , 2011, 129, 243.	2.4	42
97	Patient Communication and the Glaucoma Surgeon. <i>Journal of Current Glaucoma Practice</i> , 2011, 5, 1-7.	0.5	2
98	Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. <i>British Journal of Ophthalmology</i> , 2011, 95, 966-970.	3.9	11
99	Clinical trials for glaucoma neuroprotection are not impossible. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 144-154.	2.9	63
100	Mitomycin Câ€™Augmented Trabeculectomy Combined With Single-Site Manual Small-Incision Cataract Surgery Through a Tunnel Flap Technique. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 142-146.	2.5	3
101	What's new in laser treatment for glaucoma?. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 111-117.	2.9	25
102	Patient Race, Reported Problems in Using Glaucoma Medications, and Adherence. <i>ISRN Ophthalmology</i> , 2012, 2012, 1-7.	1.7	27
103	Determinants of Medication Adherence to Topical Glaucoma Therapy. <i>Journal of Glaucoma</i> , 2012, 21, 234-240.	1.6	117
104	Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network. <i>European Journal of Ophthalmology</i> , 2012, 22, 376-387.	1.3	1
105	A 2-hour Information Session and Patient Recall has Minimal Impact on Glaucoma-treatment Persistence in a Mature Practice. <i>Journal of Glaucoma</i> , 2012, 21, 379-382.	1.6	8
106	Selective Laser Trabeculoplasty Versus Medical Therapy as Initial Treatment of Glaucoma. <i>Journal of Glaucoma</i> , 2012, 21, 460-468.	1.6	157
107	Comparative Study of In Vitro Ocular Surface Cytotoxicity of a Fixed Combination of 0.5% Timolol/1% Dorzolamide Eyedrop and Its Components with 0.005% Benzalkonium Chloride. <i>Biocontrol Science</i> , 2012, 17, 115-120.	0.8	6
108	Influence of Parental Health Literacy and Dosing Responsibility on Pediatric Glaucoma Medication Adherence. <i>JAMA Ophthalmology</i> , 2012, 130, 306.	2.4	61
110	Validation of a short version of the glaucoma medication self-efficacy questionnaire. <i>British Journal of Ophthalmology</i> , 2012, 96, 258-262.	3.9	39
111	Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management. <i>BMC Ophthalmology</i> , 2012, 12, 57.	1.4	7
112	Latanoprost 0.005% Test Formulation is as Effective as Xalatan® in Patients with Ocular Hypertension and Primary Open-Angle Glaucoma. <i>European Journal of Ophthalmology</i> , 2012, 22, 19-27.	1.3	15
113	A Double-Masked Randomized Crossover Study Comparing the Effect of Latanoprost/Timolol and Brimonidine/Timolol Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 569-575.	1.4	21

#	ARTICLE	IF	CITATIONS
114	Selective Laser Trabeculoplasty: An Overview. <i>Journal of Current Glaucoma Practice</i> , 2012, 6, 79-90.	0.5	14
115	Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. <i>Current Medical Research and Opinion</i> , 2013, 29, 1201-1209.	1.9	12
116	Adherence, persistence and costâ€“consequence comparison of bimatoprost topical ocular formulations. <i>Current Medical Research and Opinion</i> , 2013, 29, 1187-1189.	1.9	5
117	An adherence based costâ€“consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. <i>Current Medical Research and Opinion</i> , 2013, 29, 1191-1200.	1.9	3
118	Noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study. <i>Japanese Journal of Ophthalmology</i> , 2013, 57, 47-56.	1.9	25
119	Glaucoma Severity and Medication Adherence in a County Hospital Population. <i>Ophthalmology</i> , 2013, 120, 1150-1157.	5.2	29
120	Adherence and Persistence. <i>Asia-Pacific Journal of Ophthalmology</i> , 2013, 2, 356-361.	2.5	13
121	Nanotechnology and glaucoma. <i>Current Opinion in Ophthalmology</i> , 2013, 24, 130-135.	2.9	26
122	Accounting for Costs, QALYs, and Capacity Constraints. <i>Medical Decision Making</i> , 2013, 33, 986-997.	2.4	15
123	How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	57
124	Glaucoma Medication Adherence among African Americans. <i>Optometry and Vision Science</i> , 2013, 90, 883-897.	1.2	40
125	Morning Dosing of Once-daily Glaucoma Medication is More Convenient and May Lead to Greater Adherence Than Evening Dosing. <i>Journal of Glaucoma</i> , 2013, 22, 1-4.	1.6	10
126	Patient-Related and System-Related Barriers to Glaucoma Follow-up in a County Hospital Population. , 2013, 54, 6542.		28
127	Pattern Laser Trabeculoplasty Intraocular Pressure Reduction Efficacy in Open-Angle Glaucoma Patients on Medical Therapy. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1862.	0.2	1
128	Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. <i>Patient Preference and Adherence</i> , 2014, 8, 853.	1.8	17
129	Provider Education about Glaucoma and Glaucoma Medications during Videotaped Medical Visits. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-7.	1.3	21
130	Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. <i>Clinical Ophthalmology</i> , 2014, 8, 927.	1.8	13
131	Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting. <i>Family Practice</i> , 2014, 31, 453-461.	1.9	39

#	ARTICLE	IF	CITATIONS
132	Provider Use of Collaborative Goal Setting with Glaucoma Patients. <i>Optometry and Vision Science</i> , 2014, 91, 549-555.	1.2	12
133	Persistence of Topical Glaucoma Medication. <i>JAMA Ophthalmology</i> , 2014, 132, 1446.	2.5	44
134	Electronic Monitoring to Assess Adherence With Once-Daily Glaucoma Medications and Risk Factors for Nonadherence. <i>JAMA Ophthalmology</i> , 2014, 132, 838.	2.5	62
135	Prospects for Lentiviral Vector Mediated Prostaglandin F Synthase Gene Delivery in Monkey Eyes<i>In vivo</i>. <i>Current Eye Research</i> , 2014, 39, 859-870.	1.5	20
136	Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2014, 58, 68-74.	1.9	30
137	InÂvivo performance of a drug-eluting contact lens to treat glaucoma for a month. <i>Biomaterials</i> , 2014, 35, 432-439.	11.4	157
138	Mirror-hat device as a drop delivery aid: A pilot study. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, 333-338.	0.7	18
139	Prevalence of self-reported early glaucoma eye drop bottle exhaustion and associated risk factors: a patient survey. <i>BMC Ophthalmology</i> , 2014, 14, 79.	1.4	13
140	In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate. <i>Acta Biomaterialia</i> , 2014, 10, 87-93.	8.3	28
141	Sustained Drug Release in Nanomedicine: A Long-Acting Nanocarrier-Based Formulation for Glaucoma. <i>ACS Nano</i> , 2014, 8, 419-429.	14.6	108
142	Examining Patient Provider Communication Regarding Cost In The Glaucoma Patient Population. <i>Value in Health</i> , 2014, 17, A287.	0.3	1
143	Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 406.	1.6	17
144	Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis. <i>Journal of Glaucoma</i> , 2015, 24, e145-e150.	1.6	13
145	Glaucoma Patient Expression of Medication Problems and Nonadherence. <i>Optometry and Vision Science</i> , 2015, 92, 537-543.	1.2	19
146	Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure. <i>Translational Vision Science and Technology</i> , 2015, 4, 1.	2.2	27
147	Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence. <i>Health Education Research</i> , 2015, 30, 693-705.	1.9	23
148	Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors. <i>Clinical Therapeutics</i> , 2015, 37, 1975-1985.	2.5	36
149	Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial. <i>Ophthalmic Epidemiology</i> , 2015, 22, 380-386.	1.7	17

#	ARTICLE	IF	CITATIONS
150	Ophthalmologistâ€™Patient Communication, Self-efficacy, and Glaucoma Medication Adherence. <i>Ophthalmology</i> , 2015, 122, 748-754.	5.2	93
151	Impact of the Introduction of Generic Latanoprost on Glaucoma Medication Adherence. <i>Ophthalmology</i> , 2015, 122, 738-747.	5.2	36
152	Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma. <i>Drugs and Aging</i> , 2015, 32, 569-581.	2.7	27
153	Patient Question-Asking About Glaucoma and Glaucoma Medications During Videotaped Medical Visits. <i>Health Communication</i> , 2015, 30, 660-668.	3.1	19
154	The Relationship Between Sociodemographic Factors and Persistence With Topical Glaucoma Medications. <i>Journal of Glaucoma</i> , 2015, 24, 69-76.	1.6	28
155	Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D. <i>JAMA Ophthalmology</i> , 2015, 133, 985.	2.5	40
156	Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment. <i>BMC Ophthalmology</i> , 2015, 15, 111.	1.4	53
157	Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug. <i>Journal of Controlled Release</i> , 2015, 220, 180-188.	9.9	39
158	Improving Medication Adherence to Reduce Vision Loss in Patients with Glaucoma: Low Hanging Fruit?. <i>Ophthalmology</i> , 2015, 122, 1280-1282.	5.2	12
159	Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 808-817.	0.9	16
160	Validation of a glaucoma knowledge assessment in glaucoma patients. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1913-1918.	1.8	10
161	Adherence to treatment in patients with open-angle glaucoma and its related factors. <i>Electronic Physician</i> , 2016, 8, 2954-2961.	0.2	32
162	Critical evaluation of latanoprostene bunod in the treatment of glaucoma. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2035-2050.	1.8	32
163	Photoprotection and Extended Drug Delivery by UV Blocking Contact Lenses. <i>Optometry and Vision Science</i> , 2016, 93, 395-403.	1.2	2
164	In Vivo Studies Evaluating the Use of Contact Lenses for Drug Delivery. <i>Optometry and Vision Science</i> , 2016, 93, 367-376.	1.2	25
165	The Maccabi Glaucoma Study. <i>Journal of Glaucoma</i> , 2016, 25, e386-e391.	1.6	13
166	Recent Advances in the Pharmacotherapy for Glaucoma. <i>Advances in Ophthalmology and Optometry</i> , 2016, 1, 371-388.	0.3	1
167	Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma. <i>American Journal of Ophthalmology</i> , 2016, 168, 78-85.	3.3	10

#	ARTICLE	IF	CITATIONS
168	Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. <i>Ophthalmology</i> , 2016, 123, 1685-1694.	5.2	93
169	Refusal of Trabeculectomy for the Fellow Eye in Collaborative Initial Glaucoma Treatment Study (CIGTS) Participants. <i>American Journal of Ophthalmology</i> , 2016, 166, 1-7.	3.3	9
170	Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications. <i>Ophthalmology and Therapy</i> , 2016, 5, 207-214.	2.3	4
171	Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts. <i>Ophthalmology</i> , 2016, 123, 2103-2112.	5.2	207
172	COST-COMPARISON OF TWO TRABECULAR MICRO-BYPASS STENTS VERSUS SELECTIVE LASER TRABECULOPLASTY OR MEDICATIONS ONLY FOR INTRAOCULAR PRESSURE CONTROL FOR PATIENTS WITH OPEN-ANGLE GLAUCOMA. <i>Value in Health</i> , 2016, 19, A301.	0.3	0
173	Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months. <i>Ophthalmology and Therapy</i> , 2016, 5, 161-172.	2.3	53
174	Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 642-649.	1.4	12
175	Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing. <i>Trials</i> , 2016, 17, 316.	1.6	9
176	Glaucoma, "the silent thief of sight" patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria. <i>BMC Ophthalmology</i> , 2016, 16, 44.	1.4	26
177	Glaucoma treatment adherence at a United Kingdom general practice. <i>Eye</i> , 2016, 30, 1118-1122.	2.1	24
178	Initial Clinical Experience With the CyPass Micro-Stent. <i>Journal of Glaucoma</i> , 2016, 25, 106-112.	1.6	85
179	Persistence of Glaucoma Therapy and Visual Field Progression. <i>Journal of Glaucoma</i> , 2016, 25, e336-e339.	1.6	0
180	A Retrospective Comparison of Primary Baerveldt Implantation versus Trabeculectomy with Mitomycin C. <i>Ophthalmology</i> , 2016, 123, 789-795.	5.2	45
181	Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service. <i>Journal of Community Health</i> , 2016, 41, 845-849.	3.8	6
182	Big data and ophthalmic research. <i>Survey of Ophthalmology</i> , 2016, 61, 443-465.	4.0	45
183	Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia " Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project. <i>Ophthalmic Epidemiology</i> , 2016, 23, 122-130.	1.7	37
185	Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence-Based Review and Potential Strategies to Improve Adherence. <i>Seminars in Ophthalmology</i> , 2017, 32, 86-90.	1.6	21
186	Should the next step in glaucoma treatment be alternative drug therapies rather than gene therapy?. <i>Expert Review of Ophthalmology</i> , 2017, 12, 1-2.	0.6	0

#	ARTICLE	IF	CITATIONS
187	Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. <i>Advances in Therapy</i> , 2017, 34, 1411-1425.	2.9	12
188	Transscleral Selective Laser Trabeculoplasty Without a Gonioscopy Lens. <i>Journal of Glaucoma</i> , 2017, 26, 201-207.	1.6	28
189	Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma. <i>Journal of Medical Economics</i> , 2017, 20, 760-766.	2.1	32
190	The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 188-194.	4.0	19
191	Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring. <i>Ophthalmology</i> , 2017, 124, 1565-1566.	5.2	48
192	Treatment patterns and medication adherence of patients with glaucoma in South Korea. <i>British Journal of Ophthalmology</i> , 2017, 101, 801-807.	3.9	61
193	Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 433-444.	1.8	46
194	Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 591-597.	1.4	6
195	Innovative alternatives in the surgical management of glaucoma with cataract surgery. <i>Expert Review of Ophthalmology</i> , 2017, 12, 403-419.	0.6	3
196	Patient-Physician Communication on Medication Cost during Glaucoma Visits. <i>Optometry and Vision Science</i> , 2017, 94, 1095-1101.	1.2	17
197	Development and pilot-testing of patient decision aid for use among Chinese patients with primary open-angle glaucoma. <i>BMJ Open Ophthalmology</i> , 2017, 2, e000100.	1.6	10
198	Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 1583-1600.	1.8	133
199	In vitro release of two anti-muscarinic drugs from soft contact lenses. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 1657-1665.	1.8	16
200	Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. <i>Ophthalmology</i> , 2018, 125, 650-663.	5.2	201
201	Patient Acceptance of Sustained Glaucoma Treatment Strategies. <i>Journal of Glaucoma</i> , 2018, 27, 328-335.	1.6	13
202	Prospective Evaluation of Two iStent [®] Trabecular Stents, One iStent Supra [®] Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes. <i>Advances in Therapy</i> , 2018, 35, 395-407.	2.9	63
203	Eye Drop Dispenser Type and Medication Possession Ratio in Patients With Glaucoma: Single-Use Containers Versus Multiple-Use Bottles. <i>American Journal of Ophthalmology</i> , 2018, 188, 9-18.	3.3	7
204	Prospective study comparing Xalatan [®] eye drops and two similar generics as to the efficacy and safety profile. <i>European Journal of Ophthalmology</i> , 2018, 28, 378-384.	1.3	10

#	ARTICLE	IF	CITATIONS
205	Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. <i>Acta Ophthalmologica</i> , 2018, 96, e577-e581.	1.1	22
206	Daylight-Mediated, Passive, and Sustained Release of the Glaucoma Drug Timolol from a Contact Lens. <i>ACS Central Science</i> , 2018, 4, 1677-1687.	11.3	22
207	The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1284-1294.	0.9	14
208	Glaucoma therapy: preservative-free for all?. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 707-717.	1.8	42
209	Nature-inspired sensors. <i>Nature Nanotechnology</i> , 2018, 13, 437-438.	31.5	6
210	Real-world Case Series of iStent or iStent inject Trabecular Micro-Bypass Stents Combined with Cataract Surgery. <i>Ophthalmology and Therapy</i> , 2019, 8, 549-561.	2.3	41
211	<p>&Three-year outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic population with primary open-angle glaucoma</p>. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 869-879.	1.8	20
212	Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 841-855.	2.1	13
213	Evaluation of Automatic Monitoring of Instillation Adherence Using Eye Dropper Bottle Sensor and Deep Learning in Patients With Glaucoma. <i>Translational Vision Science and Technology</i> , 2019, 8, 55.	2.2	6
214	Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. <i>PLoS ONE</i> , 2019, 14, e0218886.	2.5	12
215	Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1001-1010.	0.9	6
216	One-Year Comparative Evaluation of iStent or iStent inject Implantation Combined with Cataract Surgery in a Single Center. <i>Advances in Therapy</i> , 2019, 36, 2797-2810.	2.9	37
217	Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery. <i>Polymers</i> , 2019, 11, 1371.	4.5	60
218	One-Year Outcomes of Second-Generation Trabecular Micro-Bypass Stents (iStent Inject) Implantation with Cataract Surgery in Different Glaucoma Subtypes and Severities. <i>Ophthalmology and Therapy</i> , 2019, 8, 563-575.	2.3	35
219	Self-Assembled Multilayer Films for Time-Controlled Ocular Drug Delivery. <i>ACS Applied Bio Materials</i> , 2019, 2, 4173-4180.	4.6	8
220	Evolution of the treatment paradigm for maximum medical therapy in glaucoma. <i>Expert Review of Ophthalmology</i> , 2019, 14, 33-42.	0.6	2
221	Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. <i>Journal of Medical Economics</i> , 2019, 22, 390-401.	2.1	33
222	Second-Generation Trabecular Micro-Bypass Stents as Standalone Treatment for Glaucoma: A 36-Month Prospective Study. <i>Advances in Therapy</i> , 2019, 36, 1606-1617.	2.9	45

#	ARTICLE	IF	CITATIONS
223	Five-Year, Prospective, Randomized, Multi-Surgeon Trial of Two Trabecular Bypass Stents versus Prostaglandin for Newly Diagnosed Open-Angle Glaucoma. <i>Ophthalmology Glaucoma</i> , 2019, 2, 156-166.	1.9	37
224	Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation. <i>Materials Science and Engineering C</i> , 2019, 103, 109730.	7.3	11
225	Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population. <i>Clinical and Experimental Ophthalmology</i> , 2019, 47, 881-891.	2.6	5
226	Patient-Reported Nonadherence with Glaucoma Therapy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 223-228.	1.4	48
228	Intra-Scleral Ciliary Sulcus Suprachoroidal Microtube: Making Supraciliary Glaucoma Surgery Affordable. <i>Journal of the National Medical Association</i> , 2019, 111, 427-435.	0.8	4
229	<p><p>One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study</p>. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 491-499.	1.8	36
230	Intermediate Results of iStent or iStent inject Implantation Combined with Cataract Surgery in a Real-World Setting: A Longitudinal Retrospective Study. <i>Ophthalmology and Therapy</i> , 2019, 8, 87-100.	2.3	46
231	Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye. <i>Frontiers in Public Health</i> , 2019, 7, 363.	2.7	5
232	Porous poly(ϵ -caprolactone) implants: A novel strategy for efficient intraocular drug delivery. <i>Journal of Controlled Release</i> , 2019, 316, 331-348.	9.9	50
233	Conceptual design considerations for a wireless intraocular pressure sensor system for effective glaucoma management. <i>Journal of Medical Engineering and Technology</i> , 2019, 43, 457-467.	1.4	1
234	Current opinion in ophthalmology. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 117-124.	2.9	8
235	Glaucoma - Next Generation Therapeutics: Impossible to Possible. <i>Pharmaceutical Research</i> , 2019, 36, 25.	3.5	32
236	A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. <i>International Ophthalmology</i> , 2019, 39, 375-383.	1.4	14
237	Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. <i>Eye</i> , 2020, 34, 60-71.	2.1	9
238	Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma. <i>Progress in Retinal and Eye Research</i> , 2020, 76, 100801.	15.5	28
239	Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland. <i>Acta Ophthalmologica</i> , 2020, 98, 449-454.	1.1	5
240	A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma. <i>Ophthalmology Glaucoma</i> , 2020, 3, 103-113.	1.9	19
241	<p><p>Minimally Invasive Surgery in Mild-to-Moderate Glaucoma Patients in Italy: Is It Time to Change?</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 2639-2655.	1.8	7

#	ARTICLE	IF	CITATIONS
242	The effect of glaucoma treatment using high-intensity focused ultrasound on total and corneal astigmatism: a prospective multicentre study. <i>Acta Ophthalmologica</i> , 2020, 98, 833-840.	1.1	5
243	Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. <i>BMC Ophthalmology</i> , 2020, 20, 223.	1.4	5
244	Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. <i>Japanese Journal of Ophthalmology</i> , 2020, 64, 398-406.	1.9	36
245	Deconstructing aqueous humor outflow – The last 50 years. <i>Experimental Eye Research</i> , 2020, 197, 108105.	2.6	16
246	Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. <i>British Journal of Ophthalmology</i> , 2020, 104, bjophthalmol-2019-315613.	3.9	17
247	Recent Developments for the Treatment of Glaucoma. <i>Topics in Medicinal Chemistry</i> , 2020, , 189-256.	0.8	2
248	Medication Adherence in Patients With Glaucoma After Cancer Diagnosis. <i>American Journal of Ophthalmology</i> , 2020, 213, 88-96.	3.3	5
249	Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9. <i>Molecular Therapy</i> , 2020, 28, 820-829.	8.2	52
250	<p>Four-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 71-80.	1.8	23
251	Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials. <i>American Journal of Ophthalmology</i> , 2020, 216, 110-120.	3.3	10
252	Effectiveness and limitations of minimally invasive glaucoma surgery targeting Schlemm’s canal. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 6-22.	1.9	18
253	Medical anti-glaucoma therapy: Beyond the drop. <i>Veterinary Ophthalmology</i> , 2021, 24, 2-15.	1.0	24
255	Five-Year Outcomes Prospective Study of Two First-Generation Trabecular Micro-Bypass Stents (iStent®) in Open-Angle Glaucoma. <i>Current Eye Research</i> , 2021, 46, 224-231.	1.5	10
256	Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. <i>Progress in Retinal and Eye Research</i> , 2021, 82, 100901.	15.5	51
257	Primary Open-Angle Glaucoma Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P71-P150.	5.2	144
258	Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P151-P192.	5.2	26
259	Preventing glaucoma progression using the trabecular micro-bypass implant iStent inject®. A cost-effectiveness analysis. <i>Revista Brasileira De Oftalmologia</i> , 2021, 80, .	0.1	0
260	Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study. <i>BMC Ophthalmology</i> , 2021, 21, 52.	1.4	9

#	ARTICLE	IF	CITATIONS
261	Risk factors leading to trabeculectomy surgery of glaucoma patient using Japanese nationwide administrative claims data: a retrospective non-interventional cohort study. <i>BMC Ophthalmology</i> , 2021, 21, 153.	1.4	5
262	New considerations for the clinical efficacy of old and new topical glaucoma medications. <i>Australasian journal of optometry, The</i> , 2021, 104, 350-366.	1.3	7
263	Bypassing the Trabecular Meshwork: Worth It or Not?. <i>Ophthalmology Glaucoma</i> , 2021, 4, 115-116.	1.9	1
265	Review of glaucoma medication adherence monitoring in the digital health era. <i>British Journal of Ophthalmology</i> , 2023, 107, 153-159.	3.9	6
266	Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4106.	2.6	4
267	Educational intervention to adopt selective laser trabeculoplasty as first-line glaucoma treatment: Randomized controlled trial: Educational intervention on selective laser trabeculoplasty. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110183.	1.3	1
268	A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE). <i>Clinical Ophthalmology</i> , 2021, Volume 15, 2211-2217.	1.8	10
269	Investigation of visual and physical factors associated with inadequate instillation of eyedrops among patients with glaucoma. <i>PLoS ONE</i> , 2021, 16, e0251699.	2.5	6
270	Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells. <i>Pharmaceutics</i> , 2021, 13, 647.	4.5	10
271	The American Glaucoma Society 100. <i>Ophthalmology Glaucoma</i> , 2022, 5, 5-15.	1.9	3
272	Demographic, Clinical, and Psychosocial Predictors of Change in Medication Adherence in the Support, Educate, Empower Program. <i>Ophthalmology Glaucoma</i> , 2022, 5, 47-57.	1.9	5
273	Improving Adherence to Topical Medication in Patients with Glaucoma. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1477-1489.	1.8	21
274	Ocular redness “II: Progress in development of therapeutics for the management of conjunctival hyperemia. <i>Ocular Surface</i> , 2021, 21, 66-77.	4.4	7
275	Comparison of Medication Adherence Assessment Tools to Identify Glaucoma Medication Nonadherence. <i>Ophthalmology Glaucoma</i> , 2022, 5, 137-145.	1.9	4
276	Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy. <i>BMC Health Services Research</i> , 2021, 21, 824.	2.2	12
277	Microinvasive glaucoma surgery: A review of 3476 eyes. <i>Survey of Ophthalmology</i> , 2021, 66, 714-742.	4.0	32
278	Clinical and Economic Burden of Glaucoma by Disease Severity. <i>Ophthalmology Glaucoma</i> , 2021, 4, 490-503.	1.9	18
279	Short-term Outcomes and Prognostic Factors of Cataract-combined Surgery with iStent versus iStent Inject. <i>Journal of Korean Ophthalmological Society</i> , 2021, 62, 1243-1251.	0.2	2

#	ARTICLE	IF	CITATIONS
280	Adherence With Glaucoma Medications: Barriers to Success and Prospects for Improvement. <i>Current Ophthalmology Reports</i> , 2021, 9, 184-189.	1.2	0
281	Prerequisites to Use Preservative-Free Drugs in Medication Therapy of Glaucoma. <i>Oftalmologiya</i> , 2021, 18, 532-538.	0.5	3
282	Design, development, and characterization of an idebenone-loaded poly- $\hat{\mu}$ -caprolactone intravitreal implant as a new therapeutic approach for LHON treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 168, 195-207.	4.3	3
283	Depression und Angst bei Glaukom. <i>Karger Kompass Ophthalmologie</i> , 2021, 7, 136-137.	0.0	0
284	Compliance and Adherence: Lifelong Therapy for Glaucoma. , 2010, , 651-656.		1
285	Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma. , 2010, , 989-993.		1
286	Improving adherence in glaucoma patients: a systematic review of patient education methods. <i>Education Therapeutique Du Patient</i> , 2011, 3, 11-20.	1.0	2
287	Three-Year Outcomes of Second-generation Trabecular Micro-bypass Stents (iStent inject) With Phacoemulsification in Various Glaucoma Subtypes and Severities. <i>Journal of Glaucoma</i> , 2021, 30, 266-275.	1.6	22
288	Suppression of TGF- $\hat{1}2$ pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. <i>PLoS ONE</i> , 2017, 12, e0172592.	2.5	72
289	Factors affecting eye drop instillation in glaucoma patients with visual field defect. <i>PLoS ONE</i> , 2017, 12, e0185874.	2.5	12
290	Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patientsâ€™An observational cohort study. <i>PLoS ONE</i> , 2018, 13, e0191185.	2.5	27
292	Quality of life in glaucoma patients after selective laser trabeculoplasty. <i>International Journal of Ophthalmology</i> , 2017, 10, 742-748.	1.1	13
293	<p>Two-Year Multicenter Outcomes of iStent inject Trabecular Micro-Bypass Stents Combined with Phacoemulsification in Various Types of Glaucoma and Ocular Hypertension<p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3507-3517.	1.8	15
294	Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community. <i>Open Ophthalmology Journal</i> , 2010, 4, 7-11.	0.2	20
295	Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-102.	2.8	42
296	Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions. <i>Pharmaceutics</i> , 2021, 13, 28.	4.5	30
297	Patterned Laser Trabeculoplasty. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 538-545.	0.7	22
298	Ab interno trabecular bypass surgery with iStentÂ® and iStent injectÂ® for open angle glaucoma. <i>Therapeutic Delivery</i> , 2020, 11, 357-362.	2.2	2

#	ARTICLE	IF	CITATIONS
299	Comparing Three Post-Op Regiments for Management of Inflammation Post Uncomplicated Cataract Surgery. "Are Steroids Really Necessary?" Journal of Clinical & Experimental Ophthalmology, 2011, 02, .	0.1	5
300	Medical Treatment: Compliance/Adherence to Glaucoma Medications-A Challenge. Journal of Current Glaucoma Practice, 2007, , 22-25.	0.5	4
301	Revisiting the Issue of Compliance in Glaucoma. Journal of Current Glaucoma Practice, 2010, , 73-76.	0.5	1
302	How "Drug Aware"™ are our Glaucoma Patients?. Journal of Current Glaucoma Practice, 2015, 9, 33-37.	0.5	13
303	PROSPECÇÃO TECNOLÓGICA DO JABORANDI (Pilocarpus microphyllus): ESPÉCIE ECONOMICAMENTE IMPORTANTE NO NORTE E NORDESTE DO BRASIL. Revista GEINTEC, 2015, 5, 1626-1638.	0.2	7
304	Racial and Socioeconomic Differences in Eye Care Utilization among Medicare Beneficiaries with Glaucoma. Ophthalmology, 2022, 129, 397-405.	5.2	42
305	Medical Management of Glaucoma. Journal of Current Glaucoma Practice, 2009, 3, 13-17.	0.5	0
307	Pressure Lowering Medications. , 0, , .		0
309	360 Degree Selective Laser Trabeculoplasty in Mexican Population. Journal of Advanced Computational Intelligence and Intelligent Informatics, 2012, 16, 540-546.	0.9	0
310	Neuroprotection in Glaucoma. , 0, , .		0
311	Primary Open Angle Glaucoma. , 2014, , 215-241.		0
312	Medical Treatment: Adherence and Persistence. , 2016, , 273-278.		0
313	Procedural Treatments: Laser Trabeculoplasty. , 2016, , 289-301.		0
314	Patient Management. , 2019, , 189-216.		0
315	Compliance with Glaucoma Therapy with Eye Drops and its Determinants in Glaucoma Patients Presenting to Clinics Affiliated to Shiraz University of Medical Sciences. Iranian South Medical Journal, 2019, 22, 119-129.	0.1	0
316	Knowledge of Glaucoma Among Patients Attending Virtual and Face-to-Face Glaucoma Clinics. Journal of Glaucoma, 2021, 30, 325-331.	1.6	5
317	Compostos químicos isolados de extratos e óleos essenciais do gênero Zanthoxylum Linnaeus (Rutaceae) e seu potencial antimicrobiano. Hoehnea (revista), 0, 47, .	0.2	2
318	<p>Patients'™ Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications</p>. Clinical Ophthalmology, 2020, Volume 14, 3781-3788.	1.8	2

#	ARTICLE	IF	CITATIONS
319	Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis. <i>Journal of Glaucoma</i> , 2021, 30, 242-250.	1.6	6
320	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. <i>Clinical Ophthalmology</i> , 2009, 3, 117-22.	1.8	18
321	Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients. <i>International Journal of Ophthalmology</i> , 2012, 5, 714-8.	1.1	3
322	Psychometrics of a new questionnaire to assess glaucoma adherence: the Glaucoma Treatment Compliance Assessment Tool (an American Ophthalmological Society thesis). <i>Transactions of the American Ophthalmological Society</i> , 2013, 111, 1-16.	1.4	11
323	Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. <i>Annals of Medicine</i> , 2022, 54, 343-358.	3.8	21
324	Cost Utility of Schlemm's Canal Microstent Injection With Cataract Surgery for Open-angle Glaucoma in the US Medicare System. <i>Journal of Glaucoma</i> , 2022, 31, 413-422.	1.6	4
325	Effect of ATP-sensitive Potassium Channel Openers on Intraocular Pressure in Ocular Hypertensive Animal Models. , 2022, 63, 15.		4
326	Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma. <i>Drug Delivery</i> , 2022, 29, 613-623.	5.7	8
327	Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery. <i>Ophthalmology</i> , 2022, 129, 742-751.	5.2	42
328	Readability and Suitability of Online Patient Education Materials for Glaucoma. <i>Ophthalmology Glaucoma</i> , 2022, 5, 525-530.	1.9	13
329	Instillation Checking Using Long Short-Term Memories for Ophthalmology Patients. , 2021, , .		0
330	Medicine treatment of glaucoma in Australia 2012-2019: prevalence, incidence and persistence. <i>BMJ Open Ophthalmology</i> , 2021, 6, e000921.	1.6	1
331	A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle Glaucoma. <i>PharmacoEconomics - Open</i> , 2022, 6, 355-365.	1.8	2
332	Asynchronous Teleophthalmology for Monitoring Glaucoma Patients in a Rural German Region: A Retrospective Observational Pilot Study. <i>Cureus</i> , 2022, , .	0.5	0
334	Factors associated with glaucoma-specific quality of life in a US glaucoma clinic in a pilot implementation of an online computerised adaptive test (GlauCAT). <i>British Journal of Ophthalmology</i> , 2023, 107, 1079-1085.	3.9	4
335	Race and Ethnicity Differences in Disease Severity and Visual Field Progression Among Glaucoma Patients. <i>American Journal of Ophthalmology</i> , 2022, 242, 69-76.	3.3	16
336	Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility. <i>PLoS ONE</i> , 2022, 17, e0269261.	2.5	1
337	Comparison of minimally invasive glaucoma surgery with trabecular micro-bypass stent and microhook ab interno trabeculotomy performed in conjunction with cataract surgery. <i>International Journal of Ophthalmology</i> , 2022, 15, 1082-1088.	1.1	1

#	ARTICLE	IF	CITATIONS
338	Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence. Patient Preference and Adherence, 0, Volume 16, 2213-2227.	1.8	3
339	Glaucoma Treatment and Hydrogel: Current Insights and State of the Art. Gels, 2022, 8, 510.	4.5	9
340	Multicenter Effectiveness and Disease Stability Through 3 Years After iStentTrabecular Micro-Bypass with Phacoemulsification in Glaucoma and Ocular Hypertension. Clinical Ophthalmology, 0, Volume 16, 2955-2968.	1.8	5
341	Depression and Glaucoma: A Review and Considerations for Researchers and Providers. International Ophthalmology Clinics, 2022, 62, 39-44.	0.7	2
342	Branch regeneration of jaborandi submitted to diferentes types of pruning and cropping systems. Acta Agronomica, 2022, 70, .	0.1	0
343	Three-Year Outcomes of a Schlemm Canal Microstent (Hydrus Microstent) with Concomitant Phacoemulsification in Open-Angle Glaucoma. Ophthalmology Glaucoma, 2023, 6, 137-146.	1.9	4
344	Clinical and Visual Field Outcomes Following Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery. Clinical Ophthalmology, 0, Volume 16, 3193-3203.	1.8	0
345	The IOP lowering effects of â€œplanningâ€ selective laser trabeculoplasty in open angle glaucoma. Frontiers in Medicine, 0, 9, .	2.6	0
346	A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent inject implantation in Brazilian patients with glaucoma. International Ophthalmology, 2023, 43, 1665-1676.	1.4	1
347	Glaucoma and Ocular Surface Disease: More than Meets the Eye. Clinical Ophthalmology, 0, Volume 16, 3641-3649.	1.8	10
348	Wireless theranostic smart contact lens for monitoring and control of intraocular pressure in glaucoma. Nature Communications, 2022, 13, .	12.8	24
349	The case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm. Current Opinion in Ophthalmology, 2023, 34, 138-145.	2.9	4
351	Instillation checking using long shortâ€ term memories for ophthalmology patients. Concurrency Computation Practice and Experience, 0, , .	2.2	0
352	Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland. European Journal of Ophthalmology, 0, , 112067212211443.	1.3	0
353	The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients. Journal of Personalized Medicine, 2022, 12, 2057.	2.5	2
354	Discomfort During Instillation Of Antihypertensives And Ocular Surface Condition In Glaucoma Patients. Russian Open Medical Journal, 2022, 11, .	0.3	1
355	Real-world efficacy of the intrascleral ciliary sulcus suprachoroidal microtube technique in Black and Afro-Latinx patients with glaucoma: a 1-year retrospective study. Therapeutic Advances in Ophthalmology, 2023, 15, 251584142211474.	1.4	1
356	Smart contact lens systems for ocular drug delivery and therapy. Advanced Drug Delivery Reviews, 2023, 196, 114817.	13.7	11

#	ARTICLE	IF	CITATIONS
357	Cost-Utility Analysis of a Medication Adherence-Enhancing Educational Intervention for Glaucoma. <i>Ophthalmology Glaucoma</i> , 2023, , .	1.9	0
358	Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	9.1	6
359	Factors Predicting Successful Selective Laser Trabeculoplasty to Prevent Glaucoma Progression to Surgery. <i>Journal of Korean Ophthalmological Society</i> , 2023, 64, 223-231.	0.2	0
360	Emerging glaucoma treatments: are we seeing an improvement in adherence?. <i>Expert Review of Ophthalmology</i> , 2023, 18, 101-111.	0.6	1
361	Eye Drop Adherence with an Eye Drop Bottle Cap Monitor. <i>Journal of Glaucoma</i> , 0, Publish Ahead of Print, .	1.6	0
362	Ab-Interno Canaloplasty and Ab-Interno Canaloplasty/Trabeculotomy in Glaucoma Patients Using the OMNI Surgical System. , 0, , .		0
363	Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery. <i>Nature Communications</i> , 2023, 14, .	12.8	10
364	Clinical Outcomes of Phacoemulsification in Japanese Patients Receiving First and Revised Second-Generation Trabecular Microbypass Stents. <i>Asia-Pacific Journal of Ophthalmology</i> , 2023, 12, 279-283.	2.5	1
365	Selective laser trabeculoplasty: physiology and effects of SLT. , 2023, , 209-216.		0
366	Nanocarriers for ocular drug delivery: Recent advances and future opportunities. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 2355-2366.	1.1	2
367	Adherence and Persistence to Medical Therapy in Glaucoma: An Overview. <i>Ophthalmology and Therapy</i> , 2023, 12, 2227-2240.	2.3	4
368	Efficacy and Safety of Pairing iStent Inject Trabecular Micro-Bypass and iAccess Precision Blade Goniotomy in Patients with Open-Angle Glaucoma. <i>Ophthalmology and Therapy</i> , 2023, 12, 1973-1987.	2.3	3
369	Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β -blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. <i>Japanese Journal of Ophthalmology</i> , 0, , .	1.9	0
370	Factors Affecting Glaucoma Medication Adherence and Interventions to Improve Adherence: A Narrative Review. <i>Ophthalmology and Therapy</i> , 2023, 12, 2863-2880.	2.3	2
371	Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats. <i>Journal of Controlled Release</i> , 2023, 362, 371-380.	9.9	0
372	Allogeneic Serum Eye Drops: A Randomized Clinical Trial to Evaluate the Clinical Effectiveness of Two Drop Sizes. <i>Ophthalmology and Therapy</i> , 2023, 12, 3347-3359.	2.3	1
373	Applications and Recent Developments of Hydrogels in Ophthalmology. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 5968-5984.	5.2	0
374	Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension. <i>Drugs</i> , 2024, 84, 83-97.	10.9	2

#	ARTICLE	IF	CITATIONS
375	Personality Traits Associated with Treatment Choice with an Explicit Statistical Prediction After an Explanation in a Negative Context: A Study in Patients with Glaucoma. <i>Clinical Ophthalmology</i> , 0, Volume 17, 3685-3691.	1.8	1
376	Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework. <i>Ophthalmic and Physiological Optics</i> , 2024, 44, 96-114.	2.0	1
377	Alternatives to Topical Glaucoma Medication for Glaucoma Management. <i>Clinical Ophthalmology</i> , 0, Volume 17, 3899-3913.	1.8	1
378	Factors affecting adherence to glaucoma medication: Patient perspective from North India. <i>Indian Journal of Ophthalmology</i> , 2024, 72, 391-396.	1.1	0
379	Short-term report of early glaucoma surgery with a clear lens extraction and an intraocular lens, OMNI canaloplasty, and a HYDRUS microstent: a case series in younger patients. <i>Frontiers in Ophthalmology</i> , 0, 3, .	0.5	0
380	Association of Psychosocial Factors with Activation Among Patients with Glaucoma. <i>Ophthalmology Glaucoma</i> , 2024, , .	1.9	0
381	Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. <i>Ophthalmology and Therapy</i> , 2024, 13, 995-1014.	2.3	0
382	7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage. <i>Advances in Therapy</i> , 2024, 41, 1481-1495.	2.9	0
383	Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension. <i>Ophthalmology</i> , 2024, , .	5.2	0
384	Prevalence of comorbidities with the potential to increase the risk of nonadherence to topical ocular hypotensive medication in patients with open-angle glaucoma. <i>Current Medical Research and Opinion</i> , 2024, 40, 647-655.	1.9	0
385	Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population. <i>Clinical Ophthalmology</i> , 0, Volume 18, 917-927.	1.8	0